Follow on Google News News By Tag * AME-527 * Rheumatoid Arthritis * anti-TNF-alpha antibody * Monoclonal Antibody * Humanized * More Tags... Industry News * Clinical Development * More Industries... News By Location Country(s) Industry News
Follow on Google News | TRIMER Biotech, LLC Acquires Humanized Anti-TNF-α Antibody from LillyTRIMER Biotech, LLC is pleased to announce the successful acquisition of AME-527, an anti-TNF-α monoclonal antibody under development by Eli Lilly and Company for autoimmune disorders.
By: Trimer Biotech, LLC The TNF-α is a validated target for the treatment of patients with autoimmune disorders like rheumatoid arthritis (RA). AME-527 is a fully humanized antibody and has been optimized through protein engineering for increased affinity for TNF-α. In phase I/II clinical trial of AME-527, eighteen patients with recurrent rheumatoid arthritis (RA) who failed at least 1 DMARD were treated. The results showed that AME-527 is well tolerated at all four (1, 3, 10, or 30 mg), six-weekly doses cohorts. Based on PK, PD, and efficacy measured by ACR response criteria, 10mg/week was selected as optimal therapy. Patients responding to AME-527 (ACR-20 or greater) were allowed to continue assigned dose or optimal dose (whichever was lower) for up to 1 year (Extended Treatment). “We are very excited about this acquisition. The clinical results to date suggest that AME-527 has the potential to improve therapeutic options for patients with autoimmune disorders” says Dr. Vinay Jain, CEO of TRIMER Biotech. TRIMER acquired full rights to develop AME-527 for all human therapeutic, prophylactic, and diagnostic uses. The company intends to continue the development of AME-527 for the treatment of RA and other autoimmune disorders including inflammatory bowel disease. About TRIMER Biotech, LLC: TRIMER Biotech is a privately held limited liability company (LLC) based in Dallas, TX. TRIMER is committed to the development of more effective and convenient anti-TNF-α antibodies for autoimmune disorders in order to increase the number of treatment options and make treatments available to a broader segment of the population. For more information about TRIMER Biotech, please visit us at www.trimerbio.com or contact us by email at info@trimerbio.com or by phone at 214 593.5000. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|